8-K filing — GeoVax Labs, Inc. (GOVX)
Filed: 2026-09-10 AccNo: 0001437749-26-030085 Size: 196 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Noble Capital Markets Maintains Outperform on Geovax Labs, Maintains $10 Price Target
Noble Capital Markets analyst Robert LeBoyer maintains Geovax Labs (NASDAQ:GOVX) with a Outperform and maintains $10 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
Geovax Labs Q2 EPS $(0.97) Beats $(2.88) Estimate
Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.88) by 66.32 percent. This is a 88.9 percent increase over losses of $(8.74) per share from the